Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12836795 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL2508512 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL6041032 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL828637 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL18218758 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL11127403 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL4749529 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL15799168 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL1361856 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL337222 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119112824-A | Immunoregulation and neurovascular interaction microsphere and preparation method and application thereof | 上海交通大学医学院附属瑞金医院 | 2024-12-13 | — | — | CN | claimed |
| CN-114479769-B | Preparation method of silica-coated paraffin phase-change nano microcapsule | 山东绿拓涂料科技有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117417435-B | Hydrophobic recombinant human collagen and preparation method and application thereof | 广州卡迪莲化妆品科技有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117417435-A | Hydrophobic recombinant human collagen and preparation method and application thereof | 广州卡迪莲化妆品科技有限公司 | 2024-01-19 | — | — | CN | claimed |
| EP-3433267-B1 | METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES | BACHEM HOLDING AG (CH) | 2022-08-24 | — | — | EP | claimed |
| CN-114479769-A | Preparation method of silicon dioxide-coated paraffin phase-change nano microcapsule | 山东绿拓涂料科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-111713588-A | Low-sugar chocolate paste and preparation method and application thereof | 汕头市甜甜乐糖果食品有限公司 | 2020-09-29 | — | — | CN | claimed |
| CN-108409935-B | Preparation method of cow hair keratin modified oily polyurethane film | 齐鲁工业大学 | 2020-08-04 | — | — | CN | claimed |
| US-20190100569-A1 | METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES | BACHEM HOLDING AG (CH) | 2019-04-04 | — | — | US | claimed |
| EP-1543040-B1 | SOLUBILISING CHITOSAN POLYMER SUBSTITUTED WITH HYDROPHILIC AND HYDROPHOBIC GROUPS | UNIV LONDON (GB) | 2019-02-13 | — | — | EP | claimed |
| WO-2017162650-A1 | METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES | BACHEM HOLDING AG (CH) | 2017-09-28 | — | — | WO | claimed |
| US-9408917-B2 | Pharmaceutical composition | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2016-08-09 | — | — | US | claimed |
| EP-0712862-B1 | Selective acylation of epsilon-amino groups in insulin | LILLY CO ELI (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1543040-A1 | SOLUBILISING POLYSACCHARIDES SUBSTITUTED WITH HYDROPHILIC AND HYDROPHOBIC GROUPS | UNIVERSITY OF STRATHCLYDE (GB) | 2005-06-22 | — | — | EP | claimed |
| WO-2004026912-A1 | SOLUBILISING POLYSACCHARIDES SUBSTITUTED WITH HYDROPHILIC AND HYDROPHOBIC GROUPS | THE UNIVERSITY OF STRATHCLYDE (GB) | 2004-04-01 | — | — | WO | claimed |
| US-RE37971-E1 | Acylation of proteins, specifically insulin and its analogs, with a fatty acid | ELI LILLY AND COMPANY | 2003-01-28 | — | — | US | claimed |
| EP-1227107-A1 | Selective acylation of E-amino groups | ELI LILLY AND COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| US-5646242-A | AMIDATION OF INSULIN OR DERIVATIVE WITH SOLUBLE, ACTIVATED FATTY ACID ESTER; ONE STEP | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | claimed |
| WO-1996015803-A1 | SELECTIVE ACYLATION OF ε-AMINO GROUPS | ELI LILLY AND COMPANY (US) | 1996-05-30 | — | — | WO | claimed |
| EP-0712862-A2 | Selective acylation of epsilon-amino groups | ELI LILLY AND COMPANY (US) | 1996-05-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100569-A1 | METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES | IAPP, GLP1R, GCG | KMT2A 3832/4885SMN1; SMN2 3295/4885DGKA 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.